News
The approval was based on data demonstrating that the biosimilar product and the reference product were highly similar, and that there were no clinically meaningful differences between the agents.
ESMO 2021, News
Pembrolizumab plus chemotherapy with or without bevacizumab could be a new standard of care for first-line therapy in metastatic cervical cancer.
ESMO 2021, News
There was no improvement in overall survival with bevacizumab.
News
The FDA has approved Lynparza® for use in combination with bevacizumab as first-line maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube or primary peritoneal cancer
News
Phase 1 study suggests that intravitreous injection of 0.004mg may be lowest effective dose.
News, Oncology
And, triplet and doublet drug regimens delay decline in quality of life in BRAF V600E metastatic CRC.
News
Addition of bevacizumab to carboplatin/pemetrexed beneficial in advanced non-small cell lung cancer
News
The researchers found that the hazard ratio for progression-free survival was 0.74 and 0.83 for atezolizimab plus bevacizumab versus sunitinib in PD-L1+ patients and intention-to-treat patients, respectively.
News
After completion of the initial bevacizumab treatment cycle, there was a significant reduction in epistaxis severity scores and RBC transfusion requirements.
News
However, locally assessed progression-free survival was 2.7 months longer in the combination group than in the monotherapy group.
